1. Scrip

Lilly inks second deal with Asian partner this week

 
• By Lisa LaMotta

The Indianapolis pharma signed a second deal with an Asian company in as many days. Eli Lilly & Co announced on 20 March that it will pay $56m up front to Chinese biotech Innovent Biologics to collaborate on several oncology compounds.

The Indianapolis pharma signed a second deal with an Asian company in as many days. Eli Lilly & Co announced on 20 March that it will pay $56m up front to Chinese biotech Innovent Biologics to collaborate on several oncology compounds.

The deal comes just a day after Lilly inked a collaboration with Korea's Hanmi Pharmaceuticals for $690m to work on a Phase II-ready autoimmune compound. Under the terms of this deal, Lilly is paying Hanmi $50m upfront, as well as milestones and royalties on the oral Bruton's tyrosine kinase (BTK) inhibitor HM71224 (

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Therapy Areas

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By Ian Haydock

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.